Eutropics to present data at the 2019 AACR meeting in Atlanta, April 2, in a poster 3164 / 17 – Identifying Bcl-2 family protein dependencies in tumors using dimerization specific antibody biomarkers as a method for predicting response to apoptosis inducing therapies:
“In combination with standard of care for acute myeloid leukemia: Zeidner, et al., “Phase II Study Incorporating a Novel BH3-Profiling Biomarker Approach of Alvocidib Followed by Cytarabine and Mitoxantrone in Relapsed/Refractory Acute Myeloid Leukemia (AML),” EHA23, Abstract PF243. The trial design relied on selecting patients using a novel functional biomarker. Eutropics’ PraediCare Dx™ Noxa test provided the patient sample readout that revealed dependence on the anti-apoptotic protein MCL1. The data from the trial indicates that a majority of patients selected using Eutropics’ PraediCare Dx™ Noxa test achieved complete remission.”
Eutropics to present clinical data on Praedicare Dx at the ASCO Annual Meeting 2016 in Chicago in an abstract entitled: Mitochondrial Profiling As a Predictive Biomarker for Response to Cytarabine-Based Treatment of Acute Myelogenous Leukemia. The work has been selected for oral presentation in Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session on June 6th.
Eutropics to present clinical data on Praedicare Dx at the AACR Annual Meeting April 18th 2016 in New Orleans, In a poster entitled: Decitabine response in FLT3-negative AML is associated with mitochondrial priming, Abstract Control #3432.
Eutropics will present clinical correlation data at the AACR meeting in Philadelphia, on April 21st in a poster titled: Mitochondrial profiling in AML patients treated with an Alvocidib containing regimen reveals MCL-1 dependency in responder bone marrow.
Eutropics Laboratory Receives CLIA Certification Approval to Begin Clinical Laboratory Operations in Support of PraediCare-Dx™ Portfolio
Eutropics and Tolero Pharmaceuticals begin a collaboration to develop a companion diagnostic for experimental CLL therapies.
Eutropics Clinical response data is published in Molecular Cancer Therapeutics.
Eutropics to Present Data on Personalized Diagnostic for AML Patient Management at ASCO 2013 (Chicago).
Eutropics Pharmaceuticals Approved to Perform Patient Samples Testing
Eutropics Pharmaceuticals Receives United States Patent Number 8,168,755 entitled, “Antibodies specific to heterodimers of Bcl-2 family and uses thereof”
Eutropics presents at the American Society of Hematology conference
Eutropics wins Phase 2 NCI-SBIR grant to develop small molecule Mcl-1 inhibitor
Eutropics Pharmaceuticals awarded NCI contract to develop companion diagnostic for guiding AML treatments
Eutropics Pharmaceuticals will present at the NCI SBIR Investor Forum at Stanford University
Eutropics will present as part of the Emerging Company and Innovator’s Showcase at the Life Sciences Summit 2010 to be held September 22-23 at SUNY at Stony Brook
Eutropics Pharmaceuticals has signed a phase 1 contract with the National Cancer Institute, Small Business Innovation Research (NCI/SBIR) to develop diagnostic test for Multiple Myeloma
Eutropics Pharmaceuticals Granted $1.9 M Phase 2 NCI-SBIR Award for the Development of Mcl-1 Targeted Therapeutic
Boston Herald Writes: Boston lures two life-sciences start-ups including Ginko Bioworks and Eutropics.
Eutropics Pharmaceuticals Receives Massachusetts Life Sciences Center Accelerator Program Award
Eutropics Pharmaceuticals Granted SBIR Award for the Development of Oncology Theranostic Program